COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis

• Status: Unknown status
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. The mechanism of indomethacin is dependent on COX-2 inhibitor.

According to data, we design the project. The purpose of this study is to determine whether COX-2 inhibitor is effective on control of Post-ERCP pancreatitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Cyclooxygenase 2 Inhibitors; Indomethacin

Criteria

Inclusion Criteria:

• Patients undergoing diagnostic or therapeutic ERCP

Exclusion Criteria:

• Unwillingness or inability to consent for the study

• Age < 18 years old

• Intrauterine pregnancy

• Breastfeeding mother

• Standard contraindications to ERCP

• Renal failure (Cr >1.4mg/dl=120umol/l)

• Acute pancreatitis within 72 hours

• Known pancreatic head mass

• Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram

• ERCP for biliary stent removal or exchange without anticipated pancreatogram;

• Known active cardiovascular or cerebrovascular disease.

• Presence of coagulopathy before the procedure or received anticoagulation therapy within three days before the procedure;